https://www.optimumcomms.com/wp-content/uploads/2026/03/AMS_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-16 07:00:222026-09-17 15:49:59Advanced Medical Solutions – Interim results for the six months ended 30 June 2026
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-11 08:53:152026-09-11 08:53:15Resolution Therapeutics completes enrollment in Phase I/II EMERALD clinical trial evaluating RTX001 in end-stage liver disease
https://www.optimumcomms.com/wp-content/uploads/2025/07/Actithera-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-10 12:03:462026-09-10 12:03:46Actithera significantly strengthens leadership team and Board as Company advances towards clinical development
https://www.optimumcomms.com/wp-content/uploads/2026/04/Scenic-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-10 08:35:202026-09-10 08:35:20Scenic Biotech Appoints Renowned Neurology Drug Development Leader Dr. Judith Walker as Chief Medical Officer
https://www.optimumcomms.com/wp-content/uploads/2026/09/Teitur-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-10 08:31:152026-09-10 08:31:15Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34
https://www.optimumcomms.com/wp-content/uploads/2026/01/Connecta_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-10 08:05:212026-09-10 08:05:21CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-09 11:21:402026-09-09 11:21:40Minoryx and Neuraxpharm complete enrolment in leriglitazone pivotal Phase 3 trial (CALYX) in adult patients with cerebral Adrenoleukodystrophy (cALD)
https://www.optimumcomms.com/wp-content/uploads/2026/02/Vianautis-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-09 08:56:342026-09-09 08:56:34ViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-09 08:32:032026-09-09 08:32:03Biocomposites to host industry symposium and present new STIMULAN® data at EBJIS-MSIS 2026
https://www.optimumcomms.com/wp-content/uploads/2026/07/simris-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-08 16:25:442026-09-08 16:25:44Simris Group confirms strategic direction and advances two amanitin-based ADC programs toward the clinic
https://www.optimumcomms.com/wp-content/uploads/2026/06/Template_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-04 08:58:332026-09-04 08:58:33Novo Nordisk Foundation – New Copenhagen facility to strengthen Europe’s quantum manufacturing capabilities
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-03 16:12:452026-09-03 16:12:45Poolbeg Pharma to Participate in Key Conferences in September 2026
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-01 08:37:022026-09-01 08:37:02Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-28 09:09:432026-08-28 09:09:43Hansa Biopharma participating in Pareto Securities’ 17th Annual Healthcare Conference 2026
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-21 10:11:462026-08-21 10:12:23Hansa Biopharma Announces Confidential Submission of Draft Registration Statement to the SEC to allow for a potential Listing of ADSs in the United States
https://www.optimumcomms.com/wp-content/uploads/2026/07/AC-Immune-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-20 12:03:212026-08-20 12:03:21AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-18 09:38:352026-08-18 09:38:35Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
https://www.optimumcomms.com/wp-content/uploads/2026/07/AC-Immune-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-11 12:03:422026-08-11 12:03:42AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-11 08:44:392026-08-11 08:44:39Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine
https://www.optimumcomms.com/wp-content/uploads/2025/04/AstronauTx_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-10 09:23:552026-08-10 09:24:48AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaborationFor more information about Optimum Strategic Communications, please get in touch.
